Making Sense of: Sensitization in Schizophrenia

Ana Weidenauer, Martin Bauer, Ulrich Sauerzopf, Lucie Bartova, Nicole Praschak-Rieder, Harald H Sitte, Siegfried Kasper, Matthäus Willeit, Ana Weidenauer, Martin Bauer, Ulrich Sauerzopf, Lucie Bartova, Nicole Praschak-Rieder, Harald H Sitte, Siegfried Kasper, Matthäus Willeit

Abstract

Sensitization is defined as a process whereby repeated intermittent exposure to a given stimulus results in an enhanced response at subsequent exposures. Next to robust findings of an increased dopamine synthesis capacity in schizophrenia, empirical data and neuroimaging studies support the notion that the mesolimbic dopamine system of patients with schizophrenia is more reactive compared with healthy controls. These studies led to the conceptualization of schizophrenia as a state of endogenous sensitization, as stronger behavioral response and increased dopamine release after amphetamine administration or exposure to stress have been observed in patients with schizophrenia. These findings have also been integrated into the neurodevelopmental model of the disorder, which assumes that vulnerable neuronal circuits undergo progressive changes during puberty and young adulthood that lead to manifest psychosis. Rodent and human studies have made an attempt to identify the exact mechanisms of sensitization of the dopaminergic system and its association with psychosis. Doing so, several epigenetic and molecular alterations associated with dopamine release, neuroplasticity, and cellular energy metabolism have been discovered. Future research aims at targeting these key proteins associated with sensitization in schizophrenia to enhance the knowledge of the pathophysiology of the illness and pave the way for an improved treatment or even prevention of this severe psychiatric disorder.

Keywords: PHNO; amphetamine; dopamine; positron emission tomography; psychosis.

© The Author 2016. Published by Oxford University Press on behalf of CINP.

Figures

Figure 1.
Figure 1.
Sensitization leads to an increase in drug effects. The dose of a drug producing half-maximal response (ED50) decreases with sensitization, so that a lower dose is needed to produce half-maximal drug effects (ED50S). Alternatively, the original ED50 will cause larger effects in the sensitized state. The opposite is found in tolerance, where the efficiency of a drug decreases and a higher dose (ED50T) is now needed to produce half-maximal effects, or where the original ED50 will now induce smaller effects.
Figure 2.
Figure 2.
Adjacent transversal slices of a positron-emission tomography image using the dopamine D2/3 receptor agonist radioligand [11C]-(+)-PHNO. Bright areas show binding to dopamine D2/3 receptors in the human striatum and brainstem substantia nigra/ventral tegmental area.

References

    1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M. (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. The American journal of psychiatry 155:761–767.
    1. Abi-Dargham A, van de Giessen E, Slifstein M, Kegeles LS, Laruelle M. (2009) Baseline and amphetamine-stimulated dopamine activity are related in drug-naive schizophrenic subjects. Biological psychiatry 65:1091–1093.
    1. Ahlenius S, Salmi P. (1994) Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol 260:177–181.
    1. Antelman SM, Eichler AJ, Black CA, Kocan D. (1980) Interchangeability of stress and amphetamine in sensitization. Science 207:329–331.
    1. APA (2013) Diagnostic and statistical manual of mental disorders: DSM-5, Fifth Edition Edition: American Psychiatric Association.
    1. Arora D, Hearing M, Haluk DM, Mirkovic K, Fajardo-Serrano A, Wessendorf MW, Watanabe M, Lujan R, Wickman K. (2011) Acute cocaine exposure weakens GABA(B) receptor-dependent G-protein-gated inwardly rectifying K+ signaling in dopamine neurons of the ventral tegmental area. The Journal of neuroscience: the official journal of the Society for Neuroscience 31:12251–12257.
    1. Ballard ME, Gallo DA, de Wit H. (2014) Amphetamine increases errors during episodic memory retrieval. J Clin Psychopharmacol 34:85–92.
    1. Becker JB, Molenda H, Hummer DL. (2001) Gender differences in the behavioral responses to cocaine and amphetamine. Implications for mechanisms mediating gender differences in drug abuse. Annals of the New York Academy of Sciences 937:172–187.
    1. Benwell ME, Balfour DJ. (1992) The effects of acute and repeated nicotine treatment on nucleus accumbens dopamine and locomotor activity. Br J Pharmacol 105:849–856.
    1. Bertz JW, Chen J, Woods JH. (2015) Effects of pramipexole on the acquisition of responding with opioid-conditioned reinforcement in the rat. Psychopharmacology (Berl) 232:209–221.
    1. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C. (2006) Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Archives of general psychiatry 63:1386–1395.
    1. Boileau I, Payer D, Houle S, Behzadi A, Rusjan PM, Tong J, Wilkins D, Selby P, George TP, Zack M, Furukawa Y, McCluskey T, Wilson AA, Kish SJ. (2012) Higher binding of the dopamine D3 receptor-preferring ligand [11C]-(+)-propyl-hexahydro-naphtho-oxazin in methamphetamine polydrug users: a positron emission tomography study. The Journal of neuroscience: the official journal of the Society for Neuroscience 32:1353–1359.
    1. Booij L, Welfeld K, Leyton M, Dagher A, Boileau I, Sibon I, Baker GB, Diksic M, Soucy JP, Pruessner JC, Cawley-Fiset E, Casey KF, Benkelfat C. (2016) Dopamine cross-sensitization between psychostimulant drugs and stress in healthy male volunteers. Transl Psychiatry 6:e740.
    1. Borges S, Gayer-Anderson C, Mondelli V. (2013) A systematic review of the activity of the hypothalamic-pituitary-adrenal axis in first episode psychosis. Psychoneuroendocrinology 38:603–611.
    1. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D. (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proceedings of the National Academy of Sciences of the United States of America 94:2569–2574.
    1. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G. (2001) Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology (Berl) 158:259–266.
    1. Caine SB, Koob GF, Parsons LH, Everitt BJ, Schwartz JC, Sokoloff P. (1997) D3 receptor test in vitro predicts decreased cocaine self-administration in rats. Neuroreport 8:2373–2377.
    1. Calipari ES, Siciliano CA, Zimmer BA, Jones SR. (2015) Brief intermittent cocaine self-administration and abstinence sensitizes cocaine effects on the dopamine transporter and increases drug seeking. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 40:728–735.
    1. Camp DM, Robinson TE. (1988) Susceptibility to sensitization. I. Sex differences in the enduring effects of chronic D-amphetamine treatment on locomotion, stereotyped behavior and brain monoamines. Behav Brain Res 30:55–68.
    1. Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annual review of pharmacology and toxicology 41:237–260.
    1. Casey KF, Cherkasova MV, Larcher K, Evans AC, Baker GB, Dagher A, Benkelfat C, Leyton M. (2013) Individual differences in frontal cortical thickness correlate with the d-amphetamine-induced striatal dopamine response in humans. The Journal of neuroscience: the official journal of the Society for Neuroscience 33:15285–15294.
    1. Chen YW, Kao HY, Min MY, Lai WS. (2014) A sex- and region-specific role of Akt1 in the modulation of methamphetamine-induced hyperlocomotion and striatal neuronal activity: implications in schizophrenia and methamphetamine-induced psychosis. Schizophr Bull 40:388–398.
    1. Collip D, Myin-Germeys I, Van Os J. (2008) Does the concept of “sensitization” provide a plausible mechanism for the putative link between the environment and schizophrenia? Schizophr Bull 34:220–225.
    1. Cope ZA, Huggins KN, Sheppard AB, Noel DM, Roane DS, Brown RW. (2010) Neonatal quinpirole treatment enhances locomotor activation and dopamine release in the nucleus accumbens core in response to amphetamine treatment in adulthood. Synapse 64:289–300.
    1. Cunningham CL, Noble D. (1992) Conditioned activation induced by ethanol: role in sensitization and conditioned place preference. Pharmacol Biochem Behav 43:307–313.
    1. Damsma G, Bottema T, Westerink BH, Tepper PG, Dijkstra D, Pugsley TA, MacKenzie RG, Heffner TG, Wikstrom H. (1993) Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol 249:R9–10.
    1. Deroche V, Marinelli M, Maccari S, Le Moal M, Simon H, Piazza PV. (1995) Stress-induced sensitization and glucocorticoids. I. Sensitization of dopamine-dependent locomotor effects of amphetamine and morphine depends on stress-induced corticosterone secretion. The Journal of neuroscience: the official journal of the Society for Neuroscience 15:7181–7188.
    1. Edeleano L. (1887) Über einige Derivate der Phenylmethacrylsäure und der Phenylisobuttersäure.
    1. El-Ghundi MB, Fan T, Karasinska JM, Yeung J, Zhou M, O’Dowd BF, George SR. (2010) Restoration of amphetamine-induced locomotor sensitization in dopamine D1 receptor-deficient mice. Psychopharmacology (Berl) 207:599–618.
    1. Ellinwood EH, Jr, Sudilovsky A, Nelson LM. (1973) Evolving behavior in the clinical and experimental amphetamine (model) psychosis. The American journal of psychiatry 130:1088–1093.
    1. Ellinwood EH, King GR, Davidson C, Lee TH. (2000) The dopamine D2/D3 antagonist DS121 potentiates the effect of cocaine on locomotion and reduces tolerance in cocaine tolerant rats. Behav Brain Res 116:169–175.
    1. Falkai P, Rossner MJ, Schulze TG, Hasan A, Brzozka MM, Malchow B, Honer WG, Schmitt A. (2015) Kraepelin revisited: schizophrenia from degeneration to failed regeneration. Mol Psychiatry 20:671–676.
    1. Farre M, de la Torre R, Mathuna BO, Roset PN, Peiro AM, Torrens M, Ortuno J, Pujadas M, Cami J. (2004) Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics. Psychopharmacology (Berl) 173:364–375.
    1. Febo M, Pira AS. (2011) Increased BOLD activation to predator stressor in subiculum and midbrain of amphetamine-sensitized maternal rats. Brain research 1382:118–127.
    1. Feinberg I. (1982) Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res 17:319–334.
    1. Flatow J, Buckley P, Miller BJ. (2013) Meta-analysis of oxidative stress in schizophrenia. Biological psychiatry 74:400–409.
    1. Fusar-Poli P, Meyer-Lindenberg A. (2013) Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull 39:33–42.
    1. Galaj E, Haynes J, Nisanov R, Ananthan S, Ranaldi R. (2016) The dopamine D3 receptor antagonist, SR 21502, facilitates extinction of cocaine conditioned place preference. Drug Alcohol Depend 159:263–266.
    1. Gillies GE, Virdee K, McArthur S, Dalley JW. (2014) Sex-dependent diversity in ventral tegmental dopaminergic neurons and developmental programing: a molecular, cellular and behavioral analysis. Neuroscience 282C:69–85.
    1. Ginovart N. (2005) Imaging the dopamine system with in vivo [11c]raclopride displacement studies: understanding the true mechanism. Mol Imaging Biol 7:45–52.
    1. Graff-Guerrero A, Redden L, Abi-Saab W, Katz DA, Houle S, Barsoum P, Bhathena A, Palaparthy R, Saltarelli MD, Kapur S. (2010) Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Int J Neuropsychopharmacol 13:273–287.
    1. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 411:86–89.
    1. Hamamura T, Fibiger HC. (1993) Enhanced stress-induced dopamine release in the prefrontal cortex of amphetamine-sensitized rats. Eur J Pharmacol 237:65–71.
    1. Henry DJ, Greene MA, White FJ. (1989) Electrophysiological effects of cocaine in the mesoaccumbens dopamine system: repeated administration. J Pharmacol Exp Ther 251:833–839.
    1. Henry DJ, White FJ. (1991) Repeated cocaine administration causes persistent enhancement of D1 dopamine receptor sensitivity within the rat nucleus accumbens. J Pharmacol Exp Ther 258:882–890.
    1. Horger BA, Roth RH. (1996) The role of mesoprefrontal dopamine neurons in stress. Crit Rev Neurobiol 10:395–418.
    1. Howes OD, Kapur S. (2009) The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr Bull 35:549–562.
    1. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM. (2009) Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Archives of general psychiatry 66:13–20.
    1. Itzhak Y, Martin JL. (1999) Effects of cocaine, nicotine, dizocipline and alcohol on mice locomotor activity: cocaine-alcohol cross-sensitization involves upregulation of striatal dopamine transporter binding sites. Brain research 818:204–211.
    1. Janowsky DS, Risch C. (1979) Amphetamine psychosis and psychotic symptoms. Psychopharmacology (Berl) 65:73–77.
    1. John WS, Newman AH, Nader MA. (2015) Differential effects of the dopamine D3 receptor antagonist PG01037 on cocaine and methamphetamine self-administration in rhesus monkeys. Neuropharmacology 92:34–43.
    1. Joyce EM, Iversen SD. (1979) The effect of morphine applied locally to mesencephalic dopamine cell bodies on spontaneous motor activity in the rat. Neurosci Lett 14:207–212.
    1. Kalivas PW, Duffy P. (1993) Time course of extracellular dopamine and behavioral sensitization to cocaine. II. Dopamine perikarya. The Journal of neuroscience: the official journal of the Society for Neuroscience 13:276–284.
    1. Kalivas PW, Richardson-Carlson R, Van Orden G. (1986) Cross-sensitization between foot shock stress and enkephalin-induced motor activity. Biological psychiatry 21:939–950.
    1. Kantor L, Park YH, Wang KK, Gnegy M. (2002) Enhanced amphetamine-mediated dopamine release develops in PC12 cells after repeated amphetamine treatment. Eur J Pharmacol 451:27–35.
    1. Kapur S. (2003) Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. The American journal of psychiatry 160:13–23.
    1. Kasper S, Barnas C, Heiden A, Volz HP, Laakmann G, Zeit H, Pfolz H. (1997) Pramipexole as adjunct to haloperidol in schizophrenia. Safety and efficacy. Eur Neuropsychopharmacol 7:65–70.
    1. Keck TM, John WS, Czoty PW, Nader MA, Newman AH. (2015) Identifying Medication Targets for Psychostimulant Addiction: Unraveling the Dopamine D3 Receptor Hypothesis. Journal of medicinal chemistry 58:5361–5380.
    1. Keiflin R, Janak PH. (2015) Dopamine Prediction Errors in Reward Learning and Addiction: From Theory to Neural Circuitry. Neuron 88:247–263.
    1. Keshavan MS, Anderson S, Pettegrew JW. (1994) Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J Psychiatr Res 28:239–265.
    1. Kim SW, Fowler JS, Skolnick P, Muench L, Kang Y, Shea C, Logan J, Kim D, Carter P, King P, Alexoff D, Volkow ND. (2014) Therapeutic doses of buspirone block D3 receptors in the living primate brain. Int J Neuropsychopharmacol 17:1257–1267.
    1. Kumakura Y, Cumming P. (2009) PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist 15:635–650.
    1. Kumakura Y, Cumming P, Vernaleken I, Buchholz HG, Siessmeier T, Heinz A, Kienast T, Bartenstein P, Grunder G. (2007) Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. The Journal of neuroscience: the official journal of the Society for Neuroscience 27:8080–8087.
    1. Laruelle M. (2000) The role of endogenous sensitization in the pathophysiology of schizophrenia: implications from recent brain imaging studies. Brain research Brain research reviews 31:371–384.
    1. Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. (1999) Increased dopamine transmission in schizophrenia: relationship to illness phases. Biological psychiatry 46:56–72.
    1. Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D’Souza CD, Erdos J, McCance E, Rosenblatt W, Fingado C, Zoghbi SS, Baldwin RM, Seibyl JP, Krystal JH, Charney DS, Innis RB. (1996) Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proceedings of the National Academy of Sciences of the United States of America 93:9235–9240.
    1. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF, et al. (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 36:1182–1190.
    1. Lataster J, Collip D, Ceccarini J, Haas D, Booij L, van Os J, Pruessner J, Van Laere K, Myin-Germeys I. (2011) Psychosocial stress is associated with in vivo dopamine release in human ventromedial prefrontal cortex: a positron emission tomography study using [(1)(8)F]fallypride. Neuroimage 58:1081–1089.
    1. Lataster T, Valmaggia L, Lardinois M, van Os J, Myin-Germeys I. (2013) Increased stress reactivity: a mechanism specifically associated with the positive symptoms of psychotic disorder. Psychol Med 43:1389–1400.
    1. Lieberman JA, Kane JM, Alvir J. (1987) Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology (Berl) 91:415–433.
    1. Lieberman JA, Sheitman BB, Kinon BJ. (1997) Neurochemical sensitization in the pathophysiology of schizophrenia: deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 17:205–229.
    1. Maple AM, Perna MK, Parlaman JP, Stanwood GD, Brown RW. (2007) Ontogenetic quinpirole treatment produces long-lasting decreases in the expression of Rgs9, but increases Rgs17 in the striatum, nucleus accumbens and frontal cortex. Eur J Neurosci 26:2532–2538.
    1. Marinelli M, Cooper DC, Baker LK, White FJ. (2003) Impulse activity of midbrain dopamine neurons modulates drug-seeking behavior. Psychopharmacology (Berl) 168:84–98.
    1. Matuskey D, Gallezot JD, Pittman B, Williams W, Wanyiri J, Gaiser E, Lee DE, Hannestad J, Lim K, Zheng MQ, Lin SF, Labaree D, Potenza MN, Carson RE, Malison RT, Ding YS. (2014) Dopamine D(3) receptor alterations in cocaine-dependent humans imaged with [(1)(1)C](+)PHNO. Drug Alcohol Depend 139:100–105.
    1. McGowan S, Lawrence AD, Sales T, Quested D, Grasby P. (2004) Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F]fluorodopa study. Archives of general psychiatry 61:134–142.
    1. Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, Weinberger DR, Berman KF. (2002) Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature neuroscience 5:267–271.
    1. Mizrahi R, Addington J, Rusjan PM, Suridjan I, Ng A, Boileau I, Pruessner JC, Remington G, Houle S, Wilson AA. (2012) Increased stress-induced dopamine release in psychosis. Biological psychiatry 71:561–567.
    1. Mizrahi R, Kenk M, Suridjan I, Boileau I, George TP, McKenzie K, Wilson AA, Houle S, Rusjan P. (2014) Stress-induced dopamine response in subjects at clinical high risk for schizophrenia with and without concurrent cannabis use. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 39:1479–1489.
    1. Mugnaini M, Iavarone L, Cavallini P, Griffante C, Oliosi B, Savoia C, Beaver J, Rabiner EA, Micheli F, Heidbreder C, Andorn A, Merlo Pich E, Bani M. (2013) Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 38:302–312.
    1. Munro CA, McCaul ME, Wong DF, Oswald LM, Zhou Y, Brasic J, Kuwabara H, Kumar A, Alexander M, Ye W, Wand GS. (2006) Sex differences in striatal dopamine release in healthy adults. Biological psychiatry 59:966–974.
    1. Narayanan S, Wallace L, Uretsky N. (1996) Spontaneous and drug-stimulated locomotor activity after the administration of pertussis toxin into the ventral tegmental area. J Psychiatry Neurosci 21:172–180.
    1. O’Daly OG, Joyce D, Stephan KE, Murray RM, Shergill SS. (2011) Functional magnetic resonance imaging investigation of the amphetamine sensitization model of schizophrenia in healthy male volunteers. Archives of general psychiatry 68:545–554.
    1. O’Daly OG, Joyce D, Tracy DK, Stephan KE, Murray RM, Shergill S. (2014. a) Amphetamine sensitisation and memory in healthy human volunteers: a functional magnetic resonance imaging study. J Psychopharmacol 28:857–865.
    1. O’Daly OG, Joyce D, Tracy DK, Azim A, Stephan KE, Murray RM, Shergill SS. (2014. b) Amphetamine sensitization alters reward processing in the human striatum and amygdala. PloS one 9:e93955.
    1. Padgett CL, Lalive AL, Tan KR, Terunuma M, Munoz MB, Pangalos MN, Martinez-Hernandez J, Watanabe M, Moss SJ, Lujan R, Luscher C, Slesinger PA. (2012) Methamphetamine-evoked depression of GABA(B) receptor signaling in GABA neurons of the VTA. Neuron 73:978–989.
    1. Park YH, Kantor L, Wang KK, Gnegy ME. (2002) Repeated, intermittent treatment with amphetamine induces neurite outgrowth in rat pheochromocytoma cells (PC12 cells). Brain research 951:43–52.
    1. Park YH, Kantor L, Guptaroy B, Zhang M, Wang KK, Gnegy ME. (2003) Repeated amphetamine treatment induces neurite outgrowth and enhanced amphetamine-stimulated dopamine release in rat pheochromocytoma cells (PC12 cells) via a protein kinase C- and mitogen activated protein kinase-dependent mechanism. J Neurochem 87:1546–1557.
    1. Paulson PE, Robinson TE. (1995) Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: a microdialysis study in behaving rats. Synapse 19:56–65.
    1. Payer DE, Behzadi A, Kish SJ, Houle S, Wilson AA, Rusjan PM, Tong J, Selby P, George TP, McCluskey T, Boileau I. (2014) Heightened D3 dopamine receptor levels in cocaine dependence and contributions to the addiction behavioral phenotype: a positron emission tomography study with [11C]-+-PHNO. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 39:311–318.
    1. Pierce RC, Kalivas PW. (1995) Amphetamine produces sensitized increases in locomotion and extracellular dopamine preferentially in the nucleus accumbens shell of rats administered repeated cocaine. J Pharmacol Exp Ther 275:1019–1029.
    1. Piras F, Schiff M, Chiapponi C, Bossu P, Muhlenhoff M, Caltagirone C, Gerardy-Schahn R, Hildebrandt H, Spalletta G. (2015) Brain structure, cognition and negative symptoms in schizophrenia are associated with serum levels of polysialic acid-modified NCAM. Transl Psychiatry 5:e658.
    1. Post R, Contel N. (1983) Human and animal studies of cocaine: Implications for development of behavioral pathology. In: Stimulants: Neurochemical, Behavioral and Clinical Perspectives. (C I, ed), pp 169–203. New York: Raven Press;.
    1. Post RM, Weiss SR, Fontana D, Pert A. (1992) Conditioned sensitization to the psychomotor stimulant cocaine. Annals of the New York Academy of Sciences 654:386–399.
    1. Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, Cooke LW, et al. (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275:1355–1366.
    1. Richtand NM. (2006) Behavioral sensitization, alternative splicing, and d3 dopamine receptor-mediated inhibitory function. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 31:2368–2375.
    1. Richtand NM, Woods SC, Berger SP, Strakowski SM. (2001) D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 25:427–443.
    1. Robertson SD, Matthies HJ, Galli A. (2009) A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 39:73–80.
    1. Robinson TE, Badiani A. (1998) Drug-induced adaptations in catecholamine systems: on the inevitability of sensitization. Adv Pharmacol 42:987–990.
    1. Robinson TE, Becker JB. (1986) Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain research 396:157–198.
    1. Robinson TE, Browman KE, Crombag HS, Badiani A. (1998) Modulation of the induction or expression of psychostimulant sensitization by the circumstances surrounding drug administration. Neurosci Biobehav Rev 22:347–354.
    1. Santos GC, Marin MT, Cruz FC, Delucia R, Planeta CS. (2009) Amphetamine- and nicotine-induced cross-sensitization in adolescent rats persists until adulthood. Addict Biol 14:270–275.
    1. Seeman P. (2011) All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS neuroscience & therapeutics 17:118–132.
    1. Segal DM, Moraes CT, Mash DC. (1997) Up-regulation of D3 dopamine receptor mRNA in the nucleus accumbens of human cocaine fatalities. Brain Res Mol Brain Res 45:335–339.
    1. Sharpe AL, Varela E, Bettinger L, Beckstead MJ. (2015) Methamphetamine self-administration in mice decreases GIRK channel-mediated currents in midbrain dopamine neurons. Int J Neuropsychopharmacol 18.
    1. Sitte HH, Freissmuth M. (2015) Amphetamines, new psychoactive drugs and the monoamine transporter cycle. Trends Pharmacol Sci 36:41–50.
    1. Soliman A, O’Driscoll GA, Pruessner J, Holahan AL, Boileau I, Gagnon D, Dagher A. (2008) Stress-induced dopamine release in humans at risk of psychosis: a [11C]raclopride PET study. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 33:2033–2041.
    1. Song R, Yang RF, Wu N, Su RB, Li J, Peng XQ, Li X, Gaal J, Xi ZX, Gardner EL. (2012) YQA14: a novel dopamine D3 receptor antagonist that inhibits cocaine self-administration in rats and mice, but not in D3 receptor-knockout mice. Addict Biol 17:259–273.
    1. Sorg BA, Kalivas PW. (1991) Effects of cocaine and footshock stress on extracellular dopamine levels in the ventral striatum. Brain research 559:29–36.
    1. Srisurapanont M, Arunpongpaisal S, Wada K, Marsden J, Ali R, Kongsakon R. (2011) Comparisons of methamphetamine psychotic and schizophrenic symptoms: a differential item functioning analysis. Prog Neuropsychopharmacol Biol Psychiatry 35:959–964.
    1. Staley JK, Mash DC. (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. The Journal of neuroscience: the official journal of the Society for Neuroscience 16:6100–6106.
    1. Steinkellner T, Mus L, Eisenrauch B, Constantinescu A, Leo D, Konrad L, Rickhag M, Sorensen G, Efimova EV, Kong E, Willeit M, Sotnikova TD, Kudlacek O, Gether U, Freissmuth M, Pollak DD, Gainetdinov RR, Sitte HH. (2014) In vivo amphetamine action is contingent on alphaCaMKII. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 39:2681–2693.
    1. Strakowski SM, Sax KW, Rosenberg HL, DelBello MP, Adler CM. (2001) Human response to repeated low-dose d-amphetamine: evidence for behavioral enhancement and tolerance. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 25:548–554.
    1. Sulzer D, Sonders MS, Poulsen NW, Galli A. (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406–433.
    1. Urban NB, Kegeles LS, Slifstein M, Xu X, Martinez D, Sakr E, Castillo F, Moadel T, O’Malley SS, Krystal JH, Abi-Dargham A. (2010) Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [(1)(1)C]raclopride. Biological psychiatry 68:689–696.
    1. van Os J, Kapur S. (2009) Schizophrenia. Lancet 374:635–645.
    1. van Rossum JM. (1966) The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Archives internationales de pharmacodynamie et de therapie 160:492–494.
    1. van Winkel R, Stefanis NC, Myin-Germeys I. (2008) Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull 34:1095–1105.
    1. Vezina P, Stewart J. (1989) The effect of dopamine receptor blockade on the development of sensitization to the locomotor activating effects of amphetamine and morphine. Brain research 499:108–120.
    1. Wearne TA, Mirzaei M, Franklin JL, Goodchild AK, Haynes PA, Cornish JL. (2015) Methamphetamine-induced sensitization is associated with alterations to the proteome of the prefrontal cortex: implications for the maintenance of psychotic disorders. J Proteome Res 14:397–410.
    1. White FJ, Wang RY. (1984) Interactions of cholecystokinin octapeptide and dopamine on nucleus accumbens neurons. Brain research 300:161–166.
    1. Wilson AA, McCormick P, Kapur S, Willeit M, Garcia A, Hussey D, Houle S, Seeman P, Ginovart N. (2005) Radiosynthesis and evaluation of [11C]-(+)-4-propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol as a potential radiotracer for in vivo imaging of the dopamine D2 high-affinity state with positron emission tomography. Journal of medicinal chemistry 48:4153–4160.
    1. Wolf ME, White FJ, Nassar R, Brooderson RJ, Khansa MR. (1993) Differential development of autoreceptor subsensitivity and enhanced dopamine release during amphetamine sensitization. J Pharmacol Exp Ther 264:249–255.
    1. Xi ZX, Newman AH, Gilbert JG, Pak AC, Peng XQ, Ashby CR, Jr, Gitajn L, Gardner EL. (2006) The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine’s rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 31:1393–1405.
    1. Young D, Scoville W. (1938) Paranoid psychosis in narcolepsy and the possible danger of benzedrine treatment. Med Clin North Am 22:637–646.
    1. Yui K, Ikemoto S, Goto K. (2002) Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis. Annals of the New York Academy of Sciences 965:292–304.
    1. Zetterstrom T, Sharp T, Marsden CA, Ungerstedt U. (1983) In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J Neurochem 41:1769–1773.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi